Abstract: An optical module includes a housing, a circuit board assembly, an optical assembly, and an optical receptacle. The housing includes first and second housings and an optical fiber adapter. The circuit board assembly includes a rigid circuit board. The optical assembly is fixed on the first housing and includes an optical processing assembly and photoelectric chips. The optical processing assembly includes a wavelength division multiplexer, a lens group located between the wavelength division multiplexer and the photoelectric ship, and a lens group located between the wavelength division multiplexer and the optical receptacle. The photoelectric chips are close to the rigid circuit board and are electrically connected to the rigid circuit board. The optical fiber adapter is arranged at an optical interface of the housing and is integrally formed with the optical interface.

Abstract: The present disclosure relates to a dual-function protein for regulating blood glucose and lipid metabolism, wherein said dual-function protein comprises a human GLP-1 analog and human FGF21. In the present disclosure, provided is a method for preparing said dual function protein, and also provided is the use of said dual-function protein in the preparation of a biological substance for treating type 2 diabetes, obesity, dyslipidemia, fatty liver disease and/or metabolic syndrome. The dual-function protein provided in the present disclosure can synergistically regulate blood glucose and lipid levels in vivo, and satisfy multiple requirements for patients with type 2 diabetes such as lowering blood glucose, relieving hepatic steatosis, reducing body weight and improving metabolic disorders of circulating lipids.

Abstract: A One Time Programmable (OTP) memory can have a memory cell, which includes two series diodes as a fuse structure.

Abstract: The present disclosure relates to a dual-function protein for regulating blood glucose and lipid metabolism, wherein said dual-function protein comprises a human GLP-1 analog and human FGF21. In the present disclosure, provided is a method for preparing said dual function protein, and also provided is the use of said dual-function protein in the preparation of a biological substance for treating type 2 diabetes, obesity, dyslipidemia, fatty liver disease and/or metabolic syndrome. The dual-function protein provided in the present disclosure can synergistically regulate blood glucose and lipid levels in vivo, and satisfy multiple requirements for patients with type 2 diabetes such as lowering blood glucose, relieving hepatic steatosis, reducing body weight and improving metabolic disorders of circulating lipids.

Abstract: A fusion protein of hFGF21 or its analogs having improved pharmaceutical properties, and use of the fusion protein in preparing medicines for treating diseases, such as diabetes, obesity, non-alcoholic fatty liver disease, dyslipidemia, and/or metabolic syndrome.

Abstract: The present disclosure relates to a dual-function protein for regulating blood glucose and lipid metabolism, wherein said dual-function protein comprises a human GLP-1 analog and human FGF21. In the present disclosure, provided is a method for preparing said dual function protein, and also provided is the use of said dual-function protein in the preparation of a biological substance for treating type 2 diabetes, obesity, dyslipidemia, fatty liver disease and/or metabolic syndrome. The dual-function protein provided in the present disclosure can synergistically regulate blood glucose and lipid levels in vivo, and satisfy multiple requirements for patients with type 2 diabetes such as lowering blood glucose, relieving hepatic steatosis, reducing body weight and improving metabolic disorders of circulating lipids.

Abstract: The invention provides methods and pharmaceutical compositions for inhibiting viral replication, particularly retroviral replication. The methods comprise administration of stibonic acid or diphenyl compounds that disrupt viral nucleocapsid binding to nucleic acids.

Abstract: The invention provides methods and pharmaceutical compositions for inhibiting viral replication, particularly retroviral replication. The methods comprise administration of stibonic acid or diphenyl compounds that disrupt viral nucleocapsid binding to nucleic acids.

Abstract: An approach for providing a female contraceptive device is disclosed. The contraceptive device has an upper portion that contacts the cervix and an outer wall. A lower portion of the contraceptive device has corrugated inner walls that form a hollow petal-shaped sections with the outer wall. Each of the petal-shaped sections has a curled edge and is capable of storing semen. The inner wall of the lower portion forms a cavity that receives the penis. The outer wall of the lower portion has surface protrusions that creates a barrier to the flow of semen, yet permits the flow of vaginal secretion. The contraceptive device occupies the upper portion of the vaginal canal, leaving the lower portion of the canal exposed to enhance sensitivity. The bulbous shape of the contraceptive device provides additional sensual stimulation for the female, while the corrugated inner walls enhance simulation for the male.